Clinical Trials Logo

High Cholesterol clinical trials

View clinical trials related to High Cholesterol.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06350604 Recruiting - Hypertension Clinical Trials

Project WHADE: A Partner-Based Physical Activity Program for Women

Start date: January 2, 2024
Phase: N/A
Study type: Interventional

This study is designed to test the feasibility and acceptability of a new method for supporting physical activity among women ages 40-65 who have risk factors for cardiovascular disease. Each participant receives a trained physical activity coach and a physical activity partner; the partner is another woman in the program. Partners communicate with each other between weekly coaching sessions to provide support for physical activity behavior change.

NCT ID: NCT06192251 Recruiting - Obesity Clinical Trials

Complete Lifestyle Medicine Intervention Program

CLIP
Start date: November 6, 2023
Phase:
Study type: Observational

This project will use a mixed design and will be conducted at the West Parry Sound Health Centre. Based on similar studies there is an expected 10% drop-out rate so 20 participants per group will be invited to aim to have 15 finish. Total participants invited over the two-year study will be 40. The participants will be followed over a Complete 6-month Lifestyle medicine Intervention Program (CLIP) involving a collaboration between physicians, health coach, registered dietitians, and kinesiology. The CLIP will cover the 6 pillars of lifestyle medicine in 12-14 fundamentals of lifestyle medicine group classes.

NCT ID: NCT06005597 Recruiting - Clinical trials for Hypercholesterolemia

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

TANDEM
Start date: March 1, 2024
Phase: Phase 3
Study type: Interventional

The study is a placebo-controlled, double-blind, randomized, phase 3 study in participants with heterozygous familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD) or multiple ASCVD risk factors to evaluate the efficacy, safety and tolerability of obicetrapib 10mg and ezetimibe 10mg fixed dose combination as an adjunct to diet and maximally tolerated lipid-lowering therapy.